Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

C3743

Sigma-Aldrich

CI 976

>98% (HPLC), solid

Synonym(e):

2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C23H39NO4
CAS-Nummer:
114289-47-3
Molekulargewicht:
393.56
MDL-Nummer:
MFCD00869662
UNSPSC-Code:
51111800
PubChem Substanz-ID:
329775044
NACRES:
NA.77

Qualitätsniveau

100

Assay

>98% (HPLC)

Form

solid

Löslichkeit

DMSO: >10 mg/mL
H2O: insoluble <2 mg/mL

Lagertemp.

2-8°C

SMILES String

CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC

InChI

1S/C23H39NO4/c1-7-8-9-10-11-12-13-14-15-23(2,3)22(25)24-21-19(27-5)16-18(26-4)17-20(21)28-6/h16-17H,7-15H2,1-6H3,(H,24,25)

InChIKey

WAFNZAURAWBNDZ-UHFFFAOYSA-N

Anwendung

CI 976 has been used as an acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor:
  • to analyze its anti-hepatitis C virus (HCV) activity in Huh7.5.1 cells
  • to treat Neuro-2a cells to test its effect on plasma membrane integrated density of α4-SEPβ2 or α6-SEPβ2β3 nicotinic acetylcholine receptors (nAChRs)
  • to study its effects on the anti-angiogenic activity of pyripyropenes in human umbilical vein endothelial cells

Biochem./physiol. Wirkung

CI-976, a new trimethoxy fatty acid anilide, is a potent and specific inhibitor of liver and intestinal acyl coenzyme A; cholesterol acyltransferase (ACAT) in vitro. CI-976 decreased non-high density lipoprotein (HDL)-cholesterol and increased HDL-cholesterol in rats with pre-established dyslipidemia. High performance gel chromatographic separation of plasma lipoproteins also revealed that CI-976, but not CL 277,082, lowered low density lipoprotein (LDL)-cholesterol and elevated HDL-cholesterol.

H-Sätze

H413

P-Sätze

P273 - P501

Gefahreneinstufungen

Aquatic Chronic 4

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Y Azuma et al.
Japanese journal of pharmacology, 79(2), 151-158 (1999-04-15)
We studied the effect of NTE-122 (trans-1,4-bis[[1-cyclohexyl-3-(4-dimethylamino phenyl) ureido]methyl]cyclohexane), a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on intracellular cholesterol esterification and the secretion of apolipoprotein B100 (apoB)-containing lipoprotein and bile acids in the human hepatoma cell line HepG2. NTE-122 markably inhibited
S Murakami et al.
General pharmacology, 27(8), 1383-1386 (1996-12-01)
1. A novel ACAT (acyl-CoA: cholesterol acyltransferase) inhibitor, HL-004, exhibited a strong inhibitory effect on the hepatic and intestinal ACAT, but was less effective on the adrenal ACAT in vitro. 2. HL-004 selectively decreased serum VLDL cholesterol, and inhibited hepatic
Y Matsui et al.
Japanese journal of pharmacology, 85(4), 423-433 (2001-06-05)
R-755 (N-(2,6-diethylphenyl)-N'-[3-(2-methylphenyl)-6,7-dihydro-5H-cyclopenta[f[l]benzothiophen-2-yl]urea), a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, has been characterized in vitro, ex vivo and in vivo. R-755 potently inhibited ACAT activities, with IC50 values from 2.5 to 64 nM, in rabbit intestinal microsomes and several cell lines (CaCo-2
S Perrey et al.
Atherosclerosis, 155(2), 359-370 (2001-03-20)
The cholesteryl ester, foam cell-enriched vulnerable plaque is a principle pharmacological target for reducing athero-thrombosis. Acyl CoA:cholesterol Acyl Transferase (ACAT) catalyzes the esterification of free cholesterol in intestine, liver, adrenal and macrophages, leading in the latter cells to intracellular cholesteryl
Daniel Drecktrah et al.
Molecular biology of the cell, 14(8), 3459-3469 (2003-08-20)
Recent studies have suggested that formation of Golgi membrane tubules involves the generation of membrane-associated lysophospholipids by a cytoplasmic Ca2+-independent phospholipase A2 (PLA2). Herein, we provide additional support for this idea by showing that inhibition of lysophospholipid reacylation by a
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.